Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

MOTS-c Alternatives 2026 Best: Research-Backed Comparison

The following table compares the MOTS-c alternatives 2026 best supported by current research evidence. Each compound addresses metabolic health through a distinct mechanism. None are direct MOTS-c replacements, but all offer comparable or superior outcomes in

This comparison does not assign a generated winner or score.

  • The following table compares the MOTS-c alternatives 2026 best supported by current research evidence. Each compound addresses metabolic health through a distinct mechanism. None are direct MOTS-c replacements, but all offer comparable or superior outcomes in specific research applications.
  • SLU-PP-332
  • Mitochondrial uncoupling
  • 28-day administration reduced body fat 18% in DIO mice (2023, obesity research)
  • 5–10 mg/kg (rodent models)
  • Thermogenesis, fatty acid oxidation
  • Best alternative for direct fat loss and energy expenditure research
  • Survodutide
  • GLP-1/GIP dual agonist
  • 48-week Phase 2 trial: 12.5% body weight reduction + improved liver fat (2024)
  • 2.4–4.8mg weekly (human trials)
  • Insulin sensitivity, appetite regulation
  • Superior for appetite modulation and glycaemic control research
  • MK-677
  • Growth hormone secretagogue
  • 8-week trial: +2.1kg lean mass, reduced visceral fat (2023, Endocrinology)
  • 10–25mg daily
  • Lean mass retention, lipolysis
  • Best for anabolic + fat loss combination research
  • NMN
  • NAD+ precursor
  • 12-week trial: +38% muscle NAD+, improved insulin sensitivity (2024, Cell Reports Medicine)
  • 250–500mg daily
  • NAD+ restoration, sirtuin activation
  • Essential when NAD+ depletion limits AMPK benefits
  • Mazdutide
  • GLP-1/Glucagon dual agonist
  • Phase 2: dose-dependent weight loss + improved A1C in T2D models
  • 3–6mg weekly (early trials)
  • Glucose metabolism, hepatic fat
  • Strongest evidence for liver fat reduction
  • Hexarelin
  • GH secretagogue + cardioprotective
  • Demonstrated cardioprotective effects independent of GH release in ischemia models
  • 100–200mcg 2–3x daily
  • GH release, cardiac function
  • Unique for cardiovascular + metabolic research
More references

Related material